X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2715) 2715
Publication (206) 206
Book Review (45) 45
Book Chapter (11) 11
Conference Proceeding (6) 6
Data Set (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2268) 2268
everolimus (2111) 2111
index medicus (1928) 1928
female (1443) 1443
male (1397) 1397
middle aged (1271) 1271
sirolimus - analogs & derivatives (1198) 1198
aged (1058) 1058
treatment outcome (1011) 1011
adult (707) 707
oncology (690) 690
sirolimus - administration & dosage (613) 613
sirolimus - adverse effects (604) 604
sirolimus - therapeutic use (555) 555
cardiac & cardiovascular systems (535) 535
time factors (495) 495
transplantation (486) 486
drug-eluting stents (450) 450
immunosuppressive agents - therapeutic use (449) 449
immunosuppressive agents - adverse effects (443) 443
risk factors (421) 421
surgery (395) 395
sirolimus (389) 389
care and treatment (379) 379
cancer (374) 374
everolimus - administration & dosage (365) 365
tor serine-threonine kinases - antagonists & inhibitors (362) 362
prosthesis design (351) 351
rapamycin (333) 333
antineoplastic agents - therapeutic use (324) 324
prospective studies (309) 309
everolimus - adverse effects (307) 307
mammalian target (304) 304
antineoplastic agents - adverse effects (299) 299
cardiovascular agents - administration & dosage (297) 297
efficacy (280) 280
coronary artery disease - therapy (277) 277
percutaneous coronary intervention - adverse effects (270) 270
retrospective studies (268) 268
carcinoma, renal cell - drug therapy (265) 265
kidney neoplasms - drug therapy (259) 259
pharmacology & pharmacy (253) 253
follow-up studies (252) 252
everolimus - therapeutic use (248) 248
aged, 80 and over (244) 244
analysis (243) 243
immunosuppressive agents - administration & dosage (243) 243
thrombosis (243) 243
kaplan-meier estimate (239) 239
immunology (238) 238
therapy (237) 237
metastasis (235) 235
coronary angiography (234) 234
research (230) 230
trial (229) 229
percutaneous coronary intervention - instrumentation (226) 226
percutaneous coronary intervention (222) 222
angiogenesis inhibitors (220) 220
disease-free survival (217) 217
mtor (210) 210
stent (210) 210
animals (208) 208
clinical trials (208) 208
sunitinib (207) 207
stents (201) 201
antineoplastic combined chemotherapy protocols - therapeutic use (199) 199
graft rejection - prevention & control (191) 191
drug-eluting stents - adverse effects (190) 190
drug therapy, combination (189) 189
kidney transplantation (188) 188
drug therapy (187) 187
cyclosporine (186) 186
medicine & public health (186) 186
implantation (184) 184
safety (184) 184
young adult (184) 184
patients (183) 183
antineoplastic combined chemotherapy protocols - adverse effects (177) 177
tumors (168) 168
survival (166) 166
chemotherapy (165) 165
health aspects (162) 162
recipients (161) 161
mtor inhibitors (160) 160
abridged index medicus (159) 159
absorbable implants (159) 159
double-blind (159) 159
urology & nephrology (157) 157
kidney neoplasms - pathology (156) 156
outcomes (155) 155
kidneys (150) 150
sorafenib (150) 150
temsirolimus (148) 148
breast cancer (147) 147
dose-response relationship, drug (147) 147
calcineurin inhibitors (146) 146
mycophenolate-mofetil (146) 146
sirolimus - pharmacology (145) 145
prognosis (144) 144
tacrolimus (142) 142
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2657) 2657
French (17) 17
Japanese (17) 17
Spanish (12) 12
German (9) 9
Italian (6) 6
Russian (4) 4
Dutch (2) 2
Hungarian (2) 2
Chinese (1) 1
Czech (1) 1
Korean (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the American Academy of Dermatology, ISSN 0190-9622, 2015, Volume 72, Issue 2, pp. 221 - 236
The last decade has spawned an exciting new era of oncotherapy in dermatology, including the development of targeted therapies for metastatic melanoma and... 
Lambrolizumab | RAS | Ipilimumab | Panniculitis | Verrucal keratosis | Autoimmune dermopathies | PI3K-AKT-mTOR pathway | Seborrheic dermatitis | Temsirolimus | Pruritus | Dermatitis | Keratoacanthoma | Autoimmune adverse effects | Vitiligo | RAF inhibitors | Immunotherapy | Immune-related toxicities | mTOR inhibitor | B-RAF | Everolimus | PI3 kinase inhibitor | Squamous cell carcinoma | Dysgeusia | Selumetinib | Dual inhibitor | MEK inhibitors | Dabrafenib | Rapamycin | PD-1 inhibitor | Trametinib | Keratotic squamoproliferative lesion | Vemurafenib | AKT inhibitor | Loss of taste | Nivolumab | MAP kinase pathway | Hedgehog signaling pathway | Taste alteration | Vismodegib | Hair loss | Keratosis pilaris | pruritus | ADVANCED CANCER | lambrolizumab | nivolumab | dysgeusia | RENAL-CELL CARCINOMA | METASTATIC MELANOMA | ipilimumab | autoimmune adverse effects | AZD6244 ARRY-142886 | MAMMALIAN TARGET | vitiligo | TASTE PAPILLA DEVELOPMENT | BRAF INHIBITORS | vismodegib | hair loss | hedgehog signaling pathway | panniculitis | keratotic squamoproliferative lesion | keratoacanthoma | taste alteration | seborrheic dermatitis | VEMURAFENIB TREATMENT | DERMATOLOGY | trametinib | keratosis pilaris | everolimus | dermatitis | immunotherapy | autoimmune dermopathies | dabrafenib | verrucal keratosis | ADVANCED SOLID TUMORS | vemurafenib | selumetinib | loss of taste | temsirolimus | immune-related toxicities | dual inhibitor | rapamycin | squamous cell carcinoma | Drug Eruptions - etiology | Molecular Targeted Therapy - adverse effects | Skin Neoplasms - drug therapy | Photosensitivity Disorders - chemically induced | Humans | Carcinoma, Squamous Cell - chemically induced | Drug Eruptions - therapy | Skin Neoplasms - chemically induced | Photosensitivity Disorders - therapy | Immunotherapy - adverse effects | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Panniculitis - chemically induced | Signal Transduction - drug effects | Antineoplastic Agents - adverse effects | Drug Eruptions - diagnosis | Alopecia - chemically induced | Mitogen-Activated Protein Kinases - drug effects | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Index Medicus
Journal Article
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 2012, Volume 104, Issue 2, pp. 93 - 113
With the advent of targeted agents for the treatment of renal cell carcinoma (RCC), overall survival has improved, and patients are being treated continuously... 
TYROSINE KINASE INHIBITORS | CONTROLLED-TRIAL | INTERFERON-ALPHA | SUNITINIB TREATMENT | CANCER-PATIENTS | VENOUS THROMBOEMBOLISM | ONCOLOGY | HEART-FAILURE | DOUBLE-BLIND | EXPANDED ACCESS PROGRAM | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Hypothyroidism - chemically induced | Pneumonia - therapy | Anorexia - therapy | Humans | Drug Eruptions - therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Kidney Neoplasms - metabolism | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Weight Loss - drug effects | Benzenesulfonates - adverse effects | Bevacizumab | TOR Serine-Threonine Kinases - antagonists & inhibitors | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Pneumonia - chemically induced | Pyrroles - adverse effects | Antineoplastic Agents - pharmacology | Carcinoma, Renal Cell - drug therapy | Everolimus | Hypothyroidism - therapy | Wound Healing - drug effects | Molecular Targeted Therapy - methods | Sirolimus - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Sirolimus - analogs & derivatives | Europe | Gastrointestinal Tract - drug effects | Cardiovascular System - drug effects | Evidence-Based Medicine | Carcinoma, Renal Cell - metabolism | Indoles - adverse effects | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Anorexia - chemically induced | Kidney Neoplasms - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Drugs | Complications and side effects | Care and treatment | Adverse and side effects | Carcinoma, Renal cell | Research | Drug therapy | Antineoplastic agents
Journal Article
JAMA, ISSN 0098-7484, 11/2015, Volume 314, Issue 20, pp. 2155 - 2163
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 6, pp. 552 - 562
Journal Article
Journal Article
Chest, ISSN 0012-3692, 02/2008, Volume 133, Issue 2, pp. 528 - 538
Journal Article
Clinical Journal of the American Society of Nephrology, ISSN 1555-9041, 01/2017, Volume 12, Issue 1, pp. 176 - 189
Journal Article